Leukemia, Lymphoblastic
15
2
2
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
20.0%
3 terminated out of 15 trials
62.5%
-24.0% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (15)
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
Breath Analysis for the Detection of Invasive Fungal Infections
"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
The SMART CART Study: Health Information Technology
Oral Health Condition and Quality of Life in Children With Leukemia
Evaluation of the Advantage in the Use of Enteral Nutrition in Children Treated for Acute Lymphoblastic Leukemia
Overweight and Obesity as Prognostic Factors for Survival in Children With Acute Lymphoblastic Leukemia
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
ETOILE : A Feasibility Study in Pediatric Patient Education
Clinical Characteristics of Patients With Leukemia and COVID-19
Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic Leukemia
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors